Description
Indication & Scope
QiBeiAn® Iparomlimab and Tuvonralimab Injection treats adult patients with recurrent or metastatic cervical cancer.
- Mechanism：Dual PD-1 and CTLA-4 immune checkpoint inhibitor combination blocks immune inhibitory signals, reactivates tumor-specific T cells to kill cervical cancer cells.
- Drug class：Combined immune checkpoint inhibitor, anti-tumor monoclonal antibody combination therapy.
- Clinical use：First-line or second-line systemic immunotherapy for recurrent and metastatic cervical cancer.
| Generic Name | Iparomlimab and Tuvonralimab Injection |
| Brand Name | QiBeiAn |
| Ingredient | Iparomlimab and Tuvonralimab Injection |
| Dosage Form | Injection |
| Package | 50mg(2ml)*1 vial/box |
| Conditions Treated | Recurrent or metastatic cervical cancer |
| Taboos | 1. Active autoimmune diseases requiring long-term immunosuppressive treatment
2. Severe hypersensitivity to monoclonal antibody preparations or excipients 3. Uncontrolled active severe infection 4. Organ transplant recipients on immunosuppressive therapy 5. Pregnant and lactating women |
| Place of origin | China |
| Priscription Type | Prescription-only |
| Storage Conditions | Store undiluted stock solution at 2°C ~ 8°C refrigerated, protect from light, prohibit freezing |
| Manufacturer | QiLu Pharmaceutical ,Ltd |
| Registration Authority | National Medical Products Administration (NMPA) |
| Approval number | S20240044 |
| Approval Date | Sept 26, 2024 |
| Shelf Life | 24 months |
How to use ?
Recommended Dose: Fixed combined dose administered by intravenous infusion.
Time: Infusion is given according to 2-week or 3-week treatment cycles.
Instructions for use: Dilute with specified infusion solvent, administer slow intravenous infusion.
Interaction: Concurrent use of systemic corticosteroids and immunosuppressants will reduce anti-tumor efficacy and increase immune-related adverse events。
Side effects: Immune-related adverse events (thyroid dysfunction, colitis, pneumonitis), fatigue, anemia, rash, infusion-related reactions。
Important Notice
This product shall only be used for post-exposure rabies prophylaxis by professional medical staff. It must be applied combined with rabies vaccine and injected via wound infiltration plus intramuscular routes as specified. Do not administer intravenously or alter the dosage at will. Hypersensitivity monitoring is required throughout the whole injection process.
Packaging & Shipping
Packaging
Original manufacturer’s packaging with secure export carton. Customized export packaging is available upon request.
Shipping Methods
Express Courier (EMS, DHL, FedEx, UPS), Air Freight, and Sea Freight. Cold-chain transportation is available for products requiring temperature-controlled logistics.
Export Support
Certificate of Analysis
GMP Certificate
Commercial Invoice
Packing List & CPP
Cold Chain Logistics
Customs Documentation
Scientific and regulatory sources
FAQ
What is the approved indication of Qibeian?
It is used for the treatment of adult patients with recurrent or metastatic cervical cancer.
What is the pharmacological mechanism of this combination drug?
It dual-blocks PD-1 and CTLA-4 immune checkpoints to reactivate anti-tumor immune responses and kill cervical cancer cells.
Why are pregnant women contraindicated for this drug?
This immune checkpoint inhibitor may cause immune-related adverse reactions and potential fetal safety risks during pregnancy.
What are the typical immune-related side effects?
It may induce thyroid dysfunction, immune colitis, pneumonitis, rash and infusion-related allergic reactions.
QiBeiAn® | Iparomlimab and Tuvonralimab Injection | Cervical Cancer | DengYueRX
INN: Iparomlimab and Tuvonralimab Injection
Indications: Cervical cancer
Dosage Form: Injection
Strength: 50mg(2ml)/vial
Low MOQ
WHO-GMP
Worldwide Delivery
Compliance and Regulatory Documents
Related Products
